Skip to main content
Top
Published in: Medical Oncology 4/2018

Open Access 01-04-2018 | Original Paper

The inhibition of invasion of human melanoma cells through N-cadherin knock-down

Authors: Dorota Ciołczyk-Wierzbicka, Piotr Laidler

Published in: Medical Oncology | Issue 4/2018

Login to get access

Abstract

N-cadherin seems to promote cell migration and invasion in many types of cancers. The object of this study is recognition of the possible role of N-cadherin and selected downstream protein kinases: PI3K, ERK1/2, and mTOR in cell invasion in malignant melanoma. Melanoma cells were transfected with the small interfering RNA (siRNA) that targets human N–cadherin gene (CDH2). Inhibitors LY294002 (PI3K), U0126 (ERK1/2), and everolimus (mTOR) were used to inhibit selected kinases of signalling pathways. In vitro cell invasion was studied using Matrigel and an analysis of matrix metalloproteinases MMP-2 and MMP-9 activity by gelatinase zymogram assay. Treatment of melanoma cell with either siRNA against N-cadherin or protein kinase inhibitors led to significantly decreased MMPs expression and activity, as well as diminished invasion. Both the current and the former results suggest that activation of PI3/AKT, mTOR, and ERK kinase, following N-cadherin expression, contributes not only to increased proliferation but also invasive potential of melanoma cells. The results also indicate that N-cadherin, as well as the studied kinases, should be considered as a potential target in melanoma therapy.
Literature
1.
2.
go back to reference Cavey M, Rauzi M, Lenne PF, Lecuit T. A two-tiered mechanism for stabilization and immobilization of E-cadherin. Nature. 2008;453(7196):751–6.CrossRefPubMed Cavey M, Rauzi M, Lenne PF, Lecuit T. A two-tiered mechanism for stabilization and immobilization of E-cadherin. Nature. 2008;453(7196):751–6.CrossRefPubMed
3.
go back to reference Rauzi M, Lenne PF, Lecuit T. Planar polarized actomyosin contractile flows control epithelial junction remodelling. Nature. 2010;468(7327):1110–4.CrossRefPubMed Rauzi M, Lenne PF, Lecuit T. Planar polarized actomyosin contractile flows control epithelial junction remodelling. Nature. 2010;468(7327):1110–4.CrossRefPubMed
4.
go back to reference Steinberg MS, Takeichi M. Experimental specification of cell sorting, tissue spreading, and specific spatial patterning by quantitative differences in cadherin expression. Proc Natl Acad Sci USA. 1994;91(1):206–9.CrossRefPubMedPubMedCentral Steinberg MS, Takeichi M. Experimental specification of cell sorting, tissue spreading, and specific spatial patterning by quantitative differences in cadherin expression. Proc Natl Acad Sci USA. 1994;91(1):206–9.CrossRefPubMedPubMedCentral
5.
go back to reference Yilmaz M, Christofori G. Mechanisms of motility in metastasizing cells. Mol Cancer Res. 2010;8:629–42.CrossRefPubMed Yilmaz M, Christofori G. Mechanisms of motility in metastasizing cells. Mol Cancer Res. 2010;8:629–42.CrossRefPubMed
6.
go back to reference Gomez GA, McLachlan RW, Yap AS. Productive tension: force-sensing and homeostasis of cell–cell junctions. Trends Cell Biol. 2011;21:499–505.CrossRefPubMed Gomez GA, McLachlan RW, Yap AS. Productive tension: force-sensing and homeostasis of cell–cell junctions. Trends Cell Biol. 2011;21:499–505.CrossRefPubMed
7.
go back to reference Leckband D, leDuc Q, Wang N, deRooij J. Mechanosensing at cadherin adhesions. Curr Opin Cell Biol. 2011;23:523–30.CrossRefPubMed Leckband D, leDuc Q, Wang N, deRooij J. Mechanosensing at cadherin adhesions. Curr Opin Cell Biol. 2011;23:523–30.CrossRefPubMed
9.
go back to reference Pokutta S, Choi H, Ahlsen G, Hansen SD, Weis WI. Structural and thermodynamic characterization of cadherin center dot beta-catenin center dot alpha-catenin complex formation. J Biol Chem. 2014;289(19):13589–601.CrossRefPubMedPubMedCentral Pokutta S, Choi H, Ahlsen G, Hansen SD, Weis WI. Structural and thermodynamic characterization of cadherin center dot beta-catenin center dot alpha-catenin complex formation. J Biol Chem. 2014;289(19):13589–601.CrossRefPubMedPubMedCentral
10.
go back to reference Hsu M, Meier F, Nesbit M, Hsu J, Belle P, Elder D, Herlyn M. E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol. 2000;156:1515–25.CrossRefPubMedPubMedCentral Hsu M, Meier F, Nesbit M, Hsu J, Belle P, Elder D, Herlyn M. E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol. 2000;156:1515–25.CrossRefPubMedPubMedCentral
11.
go back to reference Derycke LD, Bracke ME. N-cadherin in the spotlight of cell-cell adhesion, differentiation, embryogenesis, invasion and signaling. Int J Dev Biol. 2004;48:463–76.CrossRefPubMed Derycke LD, Bracke ME. N-cadherin in the spotlight of cell-cell adhesion, differentiation, embryogenesis, invasion and signaling. Int J Dev Biol. 2004;48:463–76.CrossRefPubMed
12.
go back to reference Jacobs K, Feys L, Vanhoecke B, Van Marck V, Bracke M. P-cadherin expression reduces melanoma growth, invasion, and responsiveness to growth factors in nude mice. Eur J Cancer Prev. 2011;20(3):207–16.CrossRefPubMed Jacobs K, Feys L, Vanhoecke B, Van Marck V, Bracke M. P-cadherin expression reduces melanoma growth, invasion, and responsiveness to growth factors in nude mice. Eur J Cancer Prev. 2011;20(3):207–16.CrossRefPubMed
13.
go back to reference Araki K, Shimura T, Suzuki H, Tsutsumi S, Wada W, Yajima T, Kobayahi T, Kubo N, Kuwano H. E/N-cadherin switch mediates cancer progression via TGF-β-induced epithelial-to-mesenchymal transition in extrahepatic cholangiocarcinoma. Br J Cancer. 2011;105(12):1885–93.CrossRefPubMedPubMedCentral Araki K, Shimura T, Suzuki H, Tsutsumi S, Wada W, Yajima T, Kobayahi T, Kubo N, Kuwano H. E/N-cadherin switch mediates cancer progression via TGF-β-induced epithelial-to-mesenchymal transition in extrahepatic cholangiocarcinoma. Br J Cancer. 2011;105(12):1885–93.CrossRefPubMedPubMedCentral
14.
go back to reference Gil D, Ciołczyk-Wierzbicka D, Dulińska-Litewka J, Żwawa K, McCubrey JA, Laidler P. The mechanism of contribution of integrin linked kinase (ILK) to epithelial mesenchymal transition (ETM). Adv Enzyme Regul. 2011;51:195–207.CrossRefPubMed Gil D, Ciołczyk-Wierzbicka D, Dulińska-Litewka J, Żwawa K, McCubrey JA, Laidler P. The mechanism of contribution of integrin linked kinase (ILK) to epithelial mesenchymal transition (ETM). Adv Enzyme Regul. 2011;51:195–207.CrossRefPubMed
17.
go back to reference Westermarck J, Kähäri VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 1999;13(8):781–92.CrossRefPubMed Westermarck J, Kähäri VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 1999;13(8):781–92.CrossRefPubMed
18.
go back to reference Shellman YG, Makela M, Norris DA. Induction of secreted matrix metalloproteinase-9 activity in human melanoma cells by extracellular matrix proteins and cytokines. Melanoma Res. 2006;16(3):207–11.CrossRefPubMed Shellman YG, Makela M, Norris DA. Induction of secreted matrix metalloproteinase-9 activity in human melanoma cells by extracellular matrix proteins and cytokines. Melanoma Res. 2006;16(3):207–11.CrossRefPubMed
19.
go back to reference Aksenenko MB, Ruksha TG. Analysis of the application of MMP-9 inhibitor in skin melanoma. Bull Exp Biol Med. 2013;154(5):594–6.CrossRefPubMed Aksenenko MB, Ruksha TG. Analysis of the application of MMP-9 inhibitor in skin melanoma. Bull Exp Biol Med. 2013;154(5):594–6.CrossRefPubMed
20.
go back to reference Aksenenko MB, Gyrylova SN, Ruksha TG. Changes in the levels of N-cadherin and PCNA in skin melanoma cells are mediated through matrix metalloproteinase 9. Bull Exp Biol Med. 2012;153(3):364–6.CrossRefPubMed Aksenenko MB, Gyrylova SN, Ruksha TG. Changes in the levels of N-cadherin and PCNA in skin melanoma cells are mediated through matrix metalloproteinase 9. Bull Exp Biol Med. 2012;153(3):364–6.CrossRefPubMed
21.
go back to reference Hazan RB, Qiao R, Keren R, Badano I, Suyama K. Cadherin switch in tumor progression. Ann N Y Acad Sci. 2004;1014:155–63.CrossRefPubMed Hazan RB, Qiao R, Keren R, Badano I, Suyama K. Cadherin switch in tumor progression. Ann N Y Acad Sci. 2004;1014:155–63.CrossRefPubMed
22.
go back to reference Ferguson J, Arozarena I, Ehrhardt M, Wellbrock C. Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion. Oncogene. 2013;32(1):86–96.CrossRefPubMed Ferguson J, Arozarena I, Ehrhardt M, Wellbrock C. Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion. Oncogene. 2013;32(1):86–96.CrossRefPubMed
23.
go back to reference Ciołczyk-Wierzbicka D, Gil D, Laidler P. The inhibition of cell proliferation using silencing of N-cadherin gene by siRNA process in human melanoma cell lines. Curr Med Chem. 2012;19(1):145–51.CrossRefPubMed Ciołczyk-Wierzbicka D, Gil D, Laidler P. The inhibition of cell proliferation using silencing of N-cadherin gene by siRNA process in human melanoma cell lines. Curr Med Chem. 2012;19(1):145–51.CrossRefPubMed
24.
go back to reference Hulit J, Suyama K, Chung S, Keren R, Agiostratidou G, Shan W, Dong X, Williams TM, Lisanti MP, Knudsen K, Hazan RB. N-cadherin signaling potentiates mammary tumor metastasis via enhanced extracellular signal-regulated kinase activation. Cancer Res. 2007;67(7):3106–16.CrossRefPubMed Hulit J, Suyama K, Chung S, Keren R, Agiostratidou G, Shan W, Dong X, Williams TM, Lisanti MP, Knudsen K, Hazan RB. N-cadherin signaling potentiates mammary tumor metastasis via enhanced extracellular signal-regulated kinase activation. Cancer Res. 2007;67(7):3106–16.CrossRefPubMed
25.
go back to reference Kamikihara T, Ishigami S, Arigami T, Matsumoto M, Okumura H, Uchikado Y, Kita Y, Kurahara H, Kijima Y, Ueno S, Natsugoe S. Clinical implications of N-cadherin expression in gastric cancer. Pathol Int. 2012;62(3):161–6.CrossRefPubMed Kamikihara T, Ishigami S, Arigami T, Matsumoto M, Okumura H, Uchikado Y, Kita Y, Kurahara H, Kijima Y, Ueno S, Natsugoe S. Clinical implications of N-cadherin expression in gastric cancer. Pathol Int. 2012;62(3):161–6.CrossRefPubMed
26.
go back to reference Wang M, Ren D, Guo W, Huang S, Wang Z, Li Q, Du H, Song L, Peng X. N-cadherin promotes epithelial-mesenchymal transition and cancer stem cell-like traits via ErbB signaling in prostate cancer cells. Int J Oncol. 2016;48:595–606.CrossRefPubMed Wang M, Ren D, Guo W, Huang S, Wang Z, Li Q, Du H, Song L, Peng X. N-cadherin promotes epithelial-mesenchymal transition and cancer stem cell-like traits via ErbB signaling in prostate cancer cells. Int J Oncol. 2016;48:595–606.CrossRefPubMed
27.
go back to reference Siret C, Terciolo Ch, Dobric A, Habib M, Germain S, Bonnier R, Lombardo D, Rigot V. André1 F. Interplay between cadherins and α2β1 integrin differentially regulates melanoma cell invasion. Br J Cancer. 2015;113(10):1445–53.CrossRefPubMedPubMedCentral Siret C, Terciolo Ch, Dobric A, Habib M, Germain S, Bonnier R, Lombardo D, Rigot V. André1 F. Interplay between cadherins and α2β1 integrin differentially regulates melanoma cell invasion. Br J Cancer. 2015;113(10):1445–53.CrossRefPubMedPubMedCentral
28.
go back to reference Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y, Johnson KR. Cadherin switching. J Cell Sci. 2008;121:727–35.CrossRefPubMed Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y, Johnson KR. Cadherin switching. J Cell Sci. 2008;121:727–35.CrossRefPubMed
29.
go back to reference Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases structure, function, and biochemistry. Circ Res. 2003;92:827–39.CrossRefPubMed Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases structure, function, and biochemistry. Circ Res. 2003;92:827–39.CrossRefPubMed
30.
go back to reference Pires I, Gomes J, Prada J, Pereira D, Queiroga FL. MMP-2 and MMP-9 expression in canine cutaneous melanocytic tumours: evidence of a relationship with tumoural malignancy. Melanoma—from early detection to treatment/Book 2. 2013; Intech. pp. 1–29. https://doi.org/10.5772/54878. Pires I, Gomes J, Prada J, Pereira D, Queiroga FL. MMP-2 and MMP-9 expression in canine cutaneous melanocytic tumours: evidence of a relationship with tumoural malignancy. Melanoma—from early detection to treatment/Book 2. 2013; Intech. pp. 1–29. https://​doi.​org/​10.​5772/​54878.
35.
go back to reference Walker A, Frei R, Lawson K. The cytoplasmic domain of N-cadherin modulates MMP-9 induction in oral squamous carcinoma cells. Int J Oncol. 2014;45(4):1699–706.CrossRefPubMedPubMedCentral Walker A, Frei R, Lawson K. The cytoplasmic domain of N-cadherin modulates MMP-9 induction in oral squamous carcinoma cells. Int J Oncol. 2014;45(4):1699–706.CrossRefPubMedPubMedCentral
37.
go back to reference Conant K, Daniele S, Bozzelli PL, Abdi T, Edwards A, Szklarczyk A, Olchefske I, Ottenheimer D, Maguire-Zeiss K. Matrix metalloproteinase activity stimulates N-cadherin shedding and the soluble N-cadherin ectodomain promotes classical microglial activation. J Neuroinflamm. 2017;14(1):56–70. https://doi.org/10.1186/s12974-017-0827-4.CrossRef Conant K, Daniele S, Bozzelli PL, Abdi T, Edwards A, Szklarczyk A, Olchefske I, Ottenheimer D, Maguire-Zeiss K. Matrix metalloproteinase activity stimulates N-cadherin shedding and the soluble N-cadherin ectodomain promotes classical microglial activation. J Neuroinflamm. 2017;14(1):56–70. https://​doi.​org/​10.​1186/​s12974-017-0827-4.CrossRef
38.
go back to reference Catalanotti F, Solit DB, Pulitzer MP, Berger MF, Scott SN, Iyriboz T, Lacouture ME, Panageas KS, Wolchok JD, Carvajal RD, Schwartz GK, Rosen N, Chapman PB. Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma. Clin Cancer Res. 2013;19(8):2257–64.CrossRefPubMedPubMedCentral Catalanotti F, Solit DB, Pulitzer MP, Berger MF, Scott SN, Iyriboz T, Lacouture ME, Panageas KS, Wolchok JD, Carvajal RD, Schwartz GK, Rosen N, Chapman PB. Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma. Clin Cancer Res. 2013;19(8):2257–64.CrossRefPubMedPubMedCentral
39.
40.
go back to reference Bentke A, Małecki J, Ostrowska B, Krzykowska-Petitjean K, Laidler P. Tanespimycin and tipifarnib exhibit synergism in inducing apoptosis in melanoma cell lines from later stages of tumor progression. Cancer Invest. 2013;31(8):545–9.CrossRefPubMed Bentke A, Małecki J, Ostrowska B, Krzykowska-Petitjean K, Laidler P. Tanespimycin and tipifarnib exhibit synergism in inducing apoptosis in melanoma cell lines from later stages of tumor progression. Cancer Invest. 2013;31(8):545–9.CrossRefPubMed
41.
go back to reference Zaytsevaa YY, Valentinoa JD, Gulhatic P, Evers BM. mTOR inhibitors in cancer therapy. Cancer Lett. 2012;319(1):1–7.CrossRef Zaytsevaa YY, Valentinoa JD, Gulhatic P, Evers BM. mTOR inhibitors in cancer therapy. Cancer Lett. 2012;319(1):1–7.CrossRef
Metadata
Title
The inhibition of invasion of human melanoma cells through N-cadherin knock-down
Authors
Dorota Ciołczyk-Wierzbicka
Piotr Laidler
Publication date
01-04-2018
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2018
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-018-1104-9

Other articles of this Issue 4/2018

Medical Oncology 4/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.